
Brian Greene Tells LMU Graduates: Embrace Your Moment in the Cosmos with Curiosity and Gratitude
LOS ANGELES, May 18, 2025 /PRNewswire/ — Brian Greene, a leading theoretical physicist and sought-after communicator of groundbreaking scientific concepts, urged those gathered Sunday for Loyola Marymount University's graduate and LMU Loyola Law School commencement to appreciate their unique existence in the cosmos, embrace their potential, and approach life with gratitude.
Addressing a rapt crowd on LMU's sun-filled Westchester campus, the best-selling author told graduates 'we have each won the most improbable cosmic lottery.' See the press kit with images and Greene's commencement video HERE.
'Think about how utterly unlikely it is that you exist,' Greene said. 'Think about the nearly infinite collection of quantum processes stretching from The Big Bang until today … yet against those astounding odds – for a brief moment of time you exist, as do I.'
Drawing on discoveries from Albert Einstein to Stephen Hawking and Carl Sagan to Edwin Hubble, Greene traced for students and attendees the arc of scientific discovery allowing us to better understand our place in the universe, and the phenomenon of our capacity to live, comprehend, and connect with one another. Greene also noted the contributions of Jesuit-educated Catholic priest Georges Lemaître, who 'used Einstein's math to catch a glimpse of the possibility that space might be expanding,' an idea widely rejected at the time, only to be established a few years later.
'We can think about the past. We can imagine the future. We can take in the universe, mind and body, with reasoning and emotion allowing us to figure out astonishing things, like how stars shine and light travels, how black holes form and time elapses, allowing for creative achievements … all created by minds like yours, like mine, and that …most certainly will continue to create great beauty, to illuminate great mystery, to experience great wonder.'
This phenomenon of human existence, Greene concluded, 'should give us all a deep sense of connection. A kind of cosmic communion, and a sense that I can summarize with one word: gratitude.'
'Gratitude for being a small transient part of this wondrous unfolding, gratitude for our capacity to come together in groups that, at their best, allow us to each realize our potential, gratitude for our capacity for courage like that of George Lemaître, to stand up to authority, to not accept easy answers, and when necessary to fight for what we believe in. Gratitude that is for human existence, for fragile, delicate, difficult, challenging, painful, exhausting, beautiful, exquisite, transcendent, human existence, however brief, however evanescent, however fleeting.'
Greene is a lifelong learner committed to intellectual inquiry, educational access, and academic excellence. Described by The Washington Post as 'the single best explainer of abstruse concepts in the world today,' he is the author of four acclaimed books that have collectively sold millions of copies worldwide. His latest best-selling release, 'Until the End of Time,' which explores the cosmos and our quest to understand it, was named one of the '100 Notable Books of 2020' by The New York Times.
Greene's books have been adapted into two Emmy and Peabody Award-winning NOVA miniseries, both of which he hosted. With journalist Tracy Day, he co-founded the World Science Festival, whose flagship events in New York and Australia have reached an audience of more than two million people, and more than 250 million people online. Greene has appeared on 'The Late Show with Stephen Colbert,' played himself in an episode of 'The Big Bang Theory,' and made cameo appearances in films including 'Frequency,' 'Maze,' and 'The Last Mimzy.' A Harvard graduate and a Rhodes Scholar, he serves as director of Columbia University's Center for Theoretical Physics.
Nearly 2,900 LMU undergraduate, graduate, and law students participated in weekend commencement celebrations, which began Saturday with Ahmir 'Questlove' Thompson addressing the undergraduate commencement ceremony.
ABOUT LOYOLA MARYMOUNT UNIVERSITY
Loyola Marymount University is one of the nation's top-ranked Catholic universities, recognized by U.S. News & World Report among the top 50 private and top five Jesuit institutions in the country, and among California's top six private schools. Founded in 1911 and rooted in the Catholic, Jesuit, and Marymount traditions, LMU enrolls 7,100 undergraduates and 3,000 graduate and law students across seven colleges and schools. The university offers 56 undergraduate majors, 57 minors, 43 master's degree programs, three doctorate programs, and 12 credential/authorization programs. With top-ranked programs in law, film and television, entrepreneurship, business, and the arts, LMU is embedded in the creative, cultural, and economic life of Los Angeles. The university generates $1.4 billion in annual economic impact. A proud member of the West Coast Conference, LMU fields 14 NCAA Division I teams and competes with purpose, pride, and integrity.
LMU news and events are found at: www.lmu.edu/news.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
6 hours ago
- Malaysian Reserve
GC Biopharma's Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal
YONGIN, South Korea, May 30, 2025 /PRNewswire/ — GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal. Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period. Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly. The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly. In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters. The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life. In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug's effectiveness in addressing organ enlargement commonly associated with the disease. Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy. 'This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase', said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal's first author. 'The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility.' 'We are thrilled to publish our encouraging phase 3 clinical trial results', stated Jae Uk Jeong, Head of R&D at GC Biopharma. 'Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome.' Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma's Hunterase and Takeda's Elaprase. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. GC Biopharma Contacts (Media) Sohee Kimshkim20@ Yelin Junyelin@ Yoonjae Nayjy6520@


Malaysian Reserve
6 hours ago
- Malaysian Reserve
Rapid AI Karyotype Total Solution From China Makes a Big Splash
MILAN, Italy, May 30, 2025 /PRNewswire/ — From May 24 to 27, 2025, the annual conference of the European Society of Human Genetics (ESHG) 2025 held successfully in Milan, Italy. Hangzhou Diagens Biotechnology Co., Ltd. ( from China, made a stunning appearance with its rapid AI karyotype total solution, which received high recognition from the attending scholars. Diagens has developed the Rapid AI karyotype total solution based on iMedImage®, a globally leading general medical imaging model. This solution integrates an automatic cell harvester, a slide preparation and staining machine, an automatic cell microscopy scanning system, and an intelligent chromosome karyotyping analysis system. By leveraging four core advantages—full automation, in-depth informatization, pioneering intelligence, and unmanned processes—it has created a new type of unmanned smart laboratory. This laboratory achieves seamless 'sample input to report output' operations, significantly enhancing the speed and efficiency of sample processing and analysis while reducing laboratory costs. This advancement sets a new benchmark for the industry. During the conference, Professor Liang Desheng from the Center for Medical Genetics at Central South University in China presented a poster titled 'iMedImage®: an end-to-end foundational model for medical image recognition and its application in chromosome analysis.' Karyotyping, the gold standard for detecting chromosomal abnormalities, remains critical for diagnosing genetic and hereditary diseases. While AI effectively identifies numerical abnormalities, detecting structural abnormalities remains challenging. This abstract introduces iMedImage®, an innovative end-to-end foundation model for medical image recognition. When applied to chromosomal abnormality detection, iMedImage® demonstrated promising performance and significantly enhanced detection capabilities, achieving a diagnostic accuracy rate of 99.59%, sensitivity of 95.83%, and specificity of 100%. Additionally, the model demonstrates outstanding performance across multiple medical imaging fields, including cellular, pathological, ultrasound, X-ray, CT, and MRI, highlighting its broad application potential. The launch of Diagens rapid AI karyotype total solution represents a significant breakthrough in the intelligentization of cell experiments. It has received high acclaim from clients in Europe, Africa, South America, Asia, and other regions, with many expressing their intention to collaborate. This showcases Diagens' leading technology and innovation capabilities in the field of AI-driven healthcare. Looking ahead, Diagens will continue to adhere to the philosophy of innovation-driven development, constantly exploring cutting-edge technologies to contribute more Chinese power to the global healthcare cause. Learn more about Diagens and its solutions, please visit its website at or contact at sales@ Photo – View original content:

Malaysian Reserve
3 days ago
- Malaysian Reserve
CorePlus Puerto Rico Publishes Groundbreaking Study on Implementing 100% Quality Control in Cervical Cytology Using Whole Slide Imaging and Artificial Intelligence
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ — CorePlus, a leading precision pathology organization in Puerto Rico, has announced the publication of a landmark study validating the use of artificial intelligence (AI) and whole slide imaging (WSI) as a 100% quality control (QC) tool in cervical cytology workflows. The study was published in the prestigious peer-reviewed journal Cancer Cytopathology, underscoring its scientific rigor and clinical relevance. Revolutionizing Cytology with AI and Digital Pathology As digital pathology continues to advance into the field of cytopathology, laboratories are exploring alternatives to traditional manual microscopy screening. CorePlus evaluated the performance of the Techcyte SureView™ system—specifically designed for digital cytopathology—on 1,442 digitized slides from ThinPrep® and SurePath™ cervical cytology samples. The slides were scanned using the 3DHISTECH P1000 DX scanner under both dry and water immersion scanning profiles. A board-certified cytopathologist reviewed AI-identified objects of interest and compared them to results obtained through traditional light microscopy. Outstanding Results and Operational Efficiency The study demonstrated that the SureView™ system using the water immersion profile significantly outperformed both dry scanning and manual microscopy in detecting squamous and glandular abnormalities. Key performance metrics included: 97% accuracy 82% sensitivity 99% specificity 98% negative predictive value 86% positive predictive value In addition to its high diagnostic performance, the AI-assisted system considerably reduced review times and improved overall workflow efficiency. A New Standard for Quality Control in Cervical Cytology Following successful validation, CorePlus has fully integrated the Techcyte SureView™ system as a 100% QC tool in its laboratory operations. This marks a major step forward in adopting digital and AI technologies to enhance diagnostic accuracy, laboratory efficiency, and patient care. 'We have been able to achieve an unprecedented level of consistency and confidence in cervical cytology screening, every PAP Counts!' Mariano de Socarraz, Founder and Chief Executive Officer at CorePlus. 'Our team is proud to contribute to the advancement of digital pathology and demonstrate its real-world clinical impact.' For access to the complete published study please visit: Implementing 100% quality control in a cervical cytology workflow using whole slide images and artificial intelligence provided by the Techcyte SureView™ System – Rivera Rolon – 2025 – Cancer Cytopathology – Wiley Online Library About CorePlus CorePlus is a state-of-the-art precision pathology organization based in Puerto Rico, committed to diagnostic excellence through innovation and technology. With a patient-centered approach and quality-driven processes, CorePlus is at the forefront of adopting artificial intelligence algorithms as decision support tools for our pathologists offering unprecedented accuracy and efficiency. About Cancer Cytopathology Cancer Cytopathology is a peer-reviewed medical journal published by the American Cancer Society. Internationally recognized, it focuses on the science and practice of cancer cytopathology. The journal publishes innovative research, clinical studies, and expert reviews aimed at improving diagnostic accuracy and outcomes in cancer management. The publication of the CorePlus study in Cancer Cytopathology highlights its significant contribution to the advancement of digital cytopathology in cancer diagnostics and quality control. About Techcyte Founded in 2013, Techcyte is transforming the practice of pathology with a unified pathology platform that digitizes lab workflows and offers AI tools that improve the efficiency and accuracy of diagnostic testing. Our mission is to positively impact the health of humans, animals, and the environment through the use of artificial intelligence. We do that by partnering with best-in-class labs, whole slide scanner manufacturers, AI vendors, diagnostic companies, hardware manufacturers, and solution providers. Together, we aim to deliver a unified clinical and anatomic pathology platform to labs and clinics around the world. Visit for more information. About Epredia Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523) offers a unique array of end-to-end instruments for pathology workflows including tissue processors, microtomes, embedding stations, and a range of 3DHistech developed whole slide scanners from the single slide Pannoramic Desk II to the Pannoramic 1000 scanner. These scanners offer a single slide to 1000 slide capacity and a throughput of up to 85 slides per hour, including overnight scanning. Visit for more information.